[Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000967:Antimony Sodium Gluconate / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D005942:Gluconates / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007671:Kidney Concentrating Ability / Q000187:drug effects*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008536:Meglumine; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds
D000981:Antiprotozoal Agents; D005942:Gluconates; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony; D000967:Antimony Sodium Gluconate
Função renal em pacientes com leishmaniose muco-cutânea tratados com antimoniais pentavalentes.